DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0200250 A1 Peng Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0200250 A1 Peng Et Al US 2014020O250A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0200250 A1 Peng et al. (43) Pub. Date: Jul. 17, 2014 (54) ANTI-CANCERAGENTS (60) Provisional application No. 61/503,957, filed on Jul. 1, 2011. (71) Applicant: UWM Research Foundation, Inc., Milwaukee, WI (US) Publication Classification (72) Inventors: Xiaohua Peng, Milwaukee, WI (US); (51) Int. Cl. Yunyan Kuang, Shanghai City (CN); C07D 207/50 (2006.01) Sheng Cao, Milwaukee, WI (US); A6II 45/06 (2006.01) Wenbing Chen, Milwaukee, WI (US); A613 L/478 (2006.01) Yibin Wang, Milwaukee, WI (US) (52) U.S. Cl. CPC .......... CO7D 207/50 (2013.O1): 46K 3/478 (73) Assignee: UWM Research Foundation, Inc., ( ); Milwaukee, WI (US (2013.01); A61K 45/06 (2013.01) ilwaukee, WI (US) USPC ......................... 514/397: 548/313.7; 435/375 (21)21) Appl. NoNo.: 14/136,0259 (57) ABSTRACT (22) Filed: Dec. 20, 2013 Described herein are compounds that may be selectively acti Related U.S. Application Data vated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the (62) Division of application No. 13/539,471, filed on Jul. 1, compounds, and methods of treating cancer using the com 2012, now Pat. No. 8,637,490. pounds. Patent Application Publication Jul. 17, 2014 Sheet 1 of 13 US 2014/0200250 A1 Compound 6 6 7 7 17a 17a 8 8 9 9 10 10 5 5 Ho - + - + - + - + - + - + - + DNA Cross-link <" ssDNA 1 2 3 4 5 6 7 8 9 O 11 12 13 14 FG. Patent Application Publication Jul. 17, 2014 Sheet 2 of 13 US 2014/0200250 A1 Fate:is: if: Gigi Pisces: is is Farsist - Sifyi. Festigi 8 & 3rces : 3:83.3 38: 838 i8::::: 3. S: S. FIG. 2A Patent Application Publication Jul. 17, 2014 Sheet 3 of 13 US 2014/0200250 A1 8:38: s s &&E st & ex: 888: 8::::: & 8 88: FEG 2B Patent Application Publication Jul. 17, 2014 Sheet 4 of 13 US 2014/0200250 A1 3888:8:3& s as es: 8:33; S3888 & 28. 38:::::::::: FG. 2C Patent Application Publication Jul. 17, 2014 Sheet 5 of 13 US 2014/0200250 A1 & 88: waaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaXaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 8-8-8-8-8-8-8-8-8-8 838 FIG. 2D Patent Application Publication Jul. 17, 2014 Sheet 6 of 13 US 2014/0200250 A1 88: 88: 8: &: 8883: 88: 888 &&. 8:888&&. so 888 88 .338 88 FIG. 2E Patent Application Publication Jul. 17, 2014 Sheet 7 of 13 US 2014/0200250 A1 H2O2 + - + + + + + + + r - - - - - - - Drug - + + + + + + 4 + h - - 3 4 5 8 9 O 1 2 3 1: S 6 FIG 3 Patent Application Publication Jul. 17, 2014 Sheet 8 of 13 US 2014/0200250 A1 1 2 5 A. 100 75 50 25 sR NC-H460 CAK-1 SN12C 100- B. 75 50 25 Donor 1 Donor 2 DOnor 3 FG. 4 Patent Application Publication Jul. 17, 2014 Sheet 9 of 13 US 2014/0200250 A1 DOrl Dr. DOrr 3 DOOf DOOr - DOr 3 A. Patent Application Publication Jul. 17, 2014 Sheet 10 of 13 US 2014/0200250 A1 irg Wr ". -- w w v. • sk. & ". s . it aw xx sa & . a- a & Patent Application Publication Jul. 17, 2014 Sheet 11 of 13 US 2014/0200250 A1 Patent Application Publication Jul. 17, 2014 Sheet 12 of 13 US 2014/0200250 A1 1 2 3 4 5, 6 f 8 9 1 O 1112 13 14 15 -- CL TTT TXT GXG AXA CXC AAA AAA CAC TAT GAG 14 6 7 8 9 FIG. 8 Patent Application Publication Jul. 17, 2014 Sheet 13 of 13 US 2014/0200250 A1 FG, 9 US 2014/020O250 A1 Jul. 17, 2014 ANT-CANCERAGENTS 10010 each R is independently selected from: CROSS-REFERENCE TO RELATED APPLICATIONS 0001. This application is a divisional of U.S. patent appli cation Ser. No. 13/539,471, filed Jul. 1, 2012, which applica X. X N e tion claims priority to U.S. Provisional Patent Application No. 61/503,957, filed on Jul. 1, 2011. The entire contents of each of these applications are hereby incorporated by refer R4a ?h Rb and Ra ?il R4b; CCC. STATEMENT REGARDING FEDERALLY 10011 each R“ and R' is independently selected from SPONSORED RESEARCH halo and OSOR: 0002 This invention was made with United States govern 0012 each Y is independently a bond or —CH2—, ment support awarded by the National Cancer Institute, Grant No. 1R15CA152914-01. The United States Government has (0013 each R is independently C-C alkyl: certain rights in this invention. 0014 n is 0, 1 or 2: SEQUENCE LISTING (0015 p is 1 or 2: 0016 each R is independently selected from optionally 0003. The instant application contains a Sequence Listing substituted alkyl: which has been submitted in text format via EFS-Web and is hereby incorporated by reference in its entirety. Said text 0017 wherein if the compound of formula (I) bears a copy, created on Oct. 30, 2012, is named ASFILED Se positive charge, it further comprises at least one counterion quenceListing-Text and is 2.270 bytes in size. Ze. 0018. In another aspect, the disclosure provides a com BACKGROUND pound of formula (Ia): 0004. Many cancer cells exhibit a disturbed intracellular redox balance, making them distinctively different from their (Ia) “healthy counterparts. Among these differences, some can cer cells are hypoxic and have an increase in bioreductive processes, while others have high intracellular concentrations of reactive oxygen species due to oxidative stress. 0005. There is a continuing need for new anti-cancer agents, particularly those that have fewer toxic side-effects. e SUMMARY / \ 0006. In one aspect, the disclosure provides a compound of formula (I): 0019 wherein: (I) (0020) R' is B(XR"), wherein each X is independently R1 selected from O and S, and each R" is independently selected from hydrogen and alkyl, or two Rare taken together to form 1N an optionally substituted 5- to 8-membered ring: (R)-Nux 0021 R is: (R), r 0007 wherein: 0008 each R" is independently —B(XR"), wherein each X is independently selected from O and S, and each R' is ul. independently selected from hydrogen and alkyl, or two R' are taken together to form an optionally substituted 5- to 8-membered ring; 0022 wherein each RandR is independently selected I0009 each R is independently selected from optionally from halo and —OSOR"; and substituted alkyl, alkoxy, amino, halo, and —CH N(R) 0023 each R is independently selected from optionally €e. 3 3 substituted alkyl. US 2014/020O250 A1 Jul. 17, 2014 0024. In another aspect, the disclosure provides a com I0038 each R is independently selected from: pound of formula (II): (II) (R'), A. A. rf and N(R): (R), R4a R4b 0025 wherein: 0039 each R* and R is independently selected from 0026 each R" is independently —B(XR"), wherein each halo and—OSOR: X is independently selected from O and S, and each R' is I0040 each R is independently optionally substituted independently selected from hydrogen and alkyl, or two R' alkyl: 0041 m is 1 or 2: are taken together to form an optionally substituted 5- to 0042 n is 0, 1 or 2: 8-membered ring; 0043 p is 2; and I0027 each R is independently selected from optionally 0044 wherein the compound further comprises at least Substituted alkyl, alkoxy, amino, halo and nitro: one counterion Z. 0028 each R is independently selected from: 0045. In another aspect, the disclosure provides a com pound of formula (III): (III) RI A. R2 ri and N(R): R4a l R4b 0029 each R" and R' is independently selected from halo and —OSOR: O R2 I0030) each R is independently optionally substituted alkyl: RI 0031 m is 1 or 2: 0046 wherein: 0032 n is 0, 1 or 2: I0047 each R" is independently selected from selected 0033 p is 2; and from the group consisting of 0034 wherein the compound further comprises at least one counterion Z. 0035. In another aspect, the disclosure provides a com pound of formula (IIa): d (IIa) R3 R2 rth RI ( ) ( ) R1 GE) R2 R3 N(R), 0048 wherein at least one R' is other than —CHO: I0036) each R' is independently —B(XR"), wherein each I0049 each R is independently selected from an electron X is independently selected from O and S, and each R' is withdrawing group; independently selected from hydrogen and alkyl, or two R' 0050 each X is independently halo: are taken together to form an optionally substituted 5- to 10051) each R“ and R' is independently selected from 8-membered ring; halo and OSOR'; and 0037 each R is independently selected from hydrogen, I0052 each R is independently selected from optionally optionally substituted alkyl, alkoxy, amino, halo and nitro: substituted alkyl: US 2014/020O250 A1 Jul. 17, 2014 0053 wherein if the compound of formula (III) bears a 0063 wherein: positive charge, it further comprises at least one counterion I0064) R' is selected from the group consisting of: Ze. 0054. In another aspect, the disclosure provides a com pound of formula (IIIa): A A R2 (IIIa)III Ns Y- R4 and R4 J)s N / y I0065 R is selected from the group consisting of Hand RI N a hydroxy protecting group; I0066 R is selected from the group consisting of Hand - P(N(CH(CH)))(OCHCHCN); and I0067 each R" is independently an electron withdrawing N RI group. 0068. In another aspect, the disclosure provides a com \ f pound of formula (Va), (Vb), (Vc), (Vd), (Ve) or (Vf): N R2 (Va) R1 0055 wherein: I0056 each R" is independently selected from selected N from the group consisting of (R2)-H 2 R4 GE) (Vb) X and N(R), I0057 each R is independently selected from an electron withdrawing group; 0058 each X is independently halo: (Vc) I0059) each R is independently selected from the group consisting of —H and —COO(alkyl), and 0060 each R is independently selected from optionally substituted alkyl: 0061 wherein if the compound of formula (III) bears a positive charge, it further comprises at least one counterion Ze.
Load more

Recommended publications
  • WO 2013/134349 Al 12 September 2013 (12.09.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/134349 Al 12 September 2013 (12.09.2013) P O P C T (51) International Patent Classification: (74) Agents: CASSIDY, Timothy, A. et al; Dority & Man A61K 45/06 (2006.01) A61P 35/00 (2006.01) ning, P.A., P O Box 1449, Greenville, SC 29602-1449 A61K 9/50 (2006.01) A61K 47/48 (2006.01) (US). A61K 9/51 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US20 13/029294 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 6 March 2013 (06.03.2013) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (26) Publication Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (30) Priority Data: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 61/607,036 6 March 2012 (06.03.2012) US TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 13/784,930 5 March 2013 (05.03.2013) US ZM, ZW.
    [Show full text]
  • Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide KAVINDRA NATH 1, DAVID S
    ANTICANCER RESEARCH 37 : 3413-3421 (2017) doi:10.21873/anticanres.11708 Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide KAVINDRA NATH 1, DAVID S. NELSON 1, JEFFREY ROMAN 1, MARY E. PUTT 2, SEUNG-CHEOL LEE 1, DENNIS B. LEEPER 3 and JERRY D. GLICKSON 1 Departments of 1Radiology and 2Biostatistics & Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, U.S.A.; 3Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, U.S.A. Abstract. Background/Aim: Since temozolomide (TMZ) is stages. However, following recurrence with metastasis, the activated under alkaline conditions, we expected lonidamine prognosis is poor. Mutationally-activated BRAF is found in (LND) to have no effect or perhaps diminish its activity, but 40-60% of all melanomas with most common substitution of initial results suggest it may actually enhance either or both valine to glutamic acid at codon 600 (p. V600E) (3). Overall short- and long-term activity of TMZ in melanoma xenografts. survival is approaching two years using agents that target this Materials and Methods: Cohorts of 5 mice with subcutaneous mutation (4, 5). MEK, RAS and other signal transduction xenografts ~5 mm in diameter were treated with saline inhibitors, in combination with mutant BRAF inhibitors, have (control (CTRL)), LND only, TMZ only or LND followed by been used to deal with melanoma resistance to these agents TMZ at t=40 min (time required for maximal tumor (6). Treatment with anti-programmed death-1 (PD-1) acidification). Results: Mean tumor volume for LND+TMZ for checkpoint inhibitor immunotherapy currently produces the period between 6 and 26 days was reduced compared to durable response in about 25% of melanoma patients (7-10).
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Photodynamic Therapy with Methyl Aminolevulinate for Primary Nodular Basal Cell Carcinoma: Results of Two Randomized Studies
    Clinical trial Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies Peter Foley, MBBS, BMedSc, MD, FACD, Michael Freeman, MBBS, FACD, Alan Menter, MB, FAAD, Gregory Siller, MBBS, FACD, Rokea A. El-Azhary, MD, PhD, FAAD, Kurt Gebauer, MBBS, FACD, Nicholas J. Lowe, MD, FAAD, Michael T. Jarratt, MD, FAAD, Dedee F. Murrell, BMBCh, MD, FAAD, Phoebe Rich, MD, FAAD, David M. Pariser, MD, FAAD, Allan R. Oseroff, MD, PhD, FAAD, Ross Barnetson, MD, FRACP, FACD, Christopher Anderson, MBBS, FACD, Steven Kossard, MBBS, FACD, Lawrence E. Gibson, MD, FAAD, and Whitney D. Tope, MPhIL, MD, FAAD From the Department of Medicine Abstract (Dermatology), The University of Background Data suggest that photodynamic therapy using topical methyl aminolevulinate Melbourne, St. Vincent’s Hospital (MAL PDT) may be a noninvasive alternative to excisional surgery for nodular basal cell Melbourne, Fitzroy, Vic., Suite 5 ACH carcinoma (BCC). In the studies described here, we investigated the histologic response, House, Benowa and Department of Dermatology, Princess Alexandra tolerability, and cosmetic outcome with MAL PDT for primary nodular BCC (£ 5 mm in depth). Hospital, Woolloongabba, Qld, Fremantle Methods Two multicenter, randomized, double-blind studies with similar design and Dermatology, Fremantle, WA, and procedures were conducted. After surface debridement and minor tumor debulking, MAL cream Department of Dermatology, St. George 160 mg/g (66 patients with 75 lesions) or placebo cream (65 patients with 75 lesions) was applied Hospital, University of New South Wales, for 3 h, followed by illumination with broad-spectrum red light (75 J/cm2, 570–670 nm).
    [Show full text]
  • Activity of Mitozolomide (NSC 353451), a New Imidazotetrazine, Against Xenografts from Human Melanomas, Sarcomas, and Lung and Colon Carcinomas
    (CANCER RESEARCH 45, 1778-1786, April 1985] Activity of Mitozolomide (NSC 353451), a New Imidazotetrazine, against Xenografts from Human Melanomas, Sarcomas, and Lung and Colon Carcinomas Oy stein Fodstad, ' Steina r Aamdal,2 Alexander Pihl, and Michael R. Boyd Norsk Hydros Institute for Cancer Research, Montebello, Oslo 3, Norway [0. F., S. Aa., A. P.] and Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20205 [0. F., M. R. B.¡ ABSTRACT In this investigation, we first tested the anticancer activity of mitozolomide against cells from different xenografted cancers in The chemosensitivity of human tumor xenografts to mitozo- a HTCF assay in vitro. When a pronounced inhibition of colony lomide, 8-carbamoyl-3-{2-chloroethyl)imidazo[5-1 -d]-1,2,3,5-te- formation was observed, we next examined in the HTCF assay trazin-4(3H)-one, was studied in 3 different assay systems. In the efficiency of the drug on a panel of tumors for each histolog concentrations of 1 to 500 ¿/g/ml,mitozolomide completely inhib ical type. Since in vitro test systems have inherent limitations ited the colony-forming ability in soft agar of cell suspensions (23), we also measured the in vivo effect of mitozolomide on the from sarcomas, melanomas, lung and colon cancers, and a same tumors, using the 6-day subrenal capsule assay in immu- mammary carcinoma. When a panel of tumors of the different nocompetent mice (1-3), as well as s.c. growing tumors in histological types was tested for its sensitivity to mitozolomide athymic, nude mice (5-7, 10, 16, 18).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti Et Al
    US008580267B2 (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti et al. (45) Date of Patent: Nov. 12, 2013 (54) IMMUNOCYTOKINES FORTUMOUR (56) References Cited THERAPY WITH CHEMOTHERAPEUTIC AGENTS FOREIGN PATENT DOCUMENTS (75) Inventors: Marta Pedretti, Zurich (CH): Dario WO O2/O59264 8, 2002 WO O3,O93478 11, 2003 Neri, Buchs (CH) WO 2004/OO2528 1, 2004 WO 2006/026020 3, 2006 (73) Assignee: Philogen S.p.A., Siena (IT) WO 2006/050834 5, 2006 WO 2007/128563 11, 2007 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Paul, William, Fundamental Immunology, 3rd Edition, Raven Press, New York, 1993, pp. 292-295.* (21) Appl. No.: 13/139,655 Vajdos et al., Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning 1-1. mutagenesis. J. Mol. Biol. 320:415-428, 2002.* (22) PCT Filed: Dec. 14, 2009 Bartolomei, M., et al. “Combined treatment of glioblastomapatients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and (86). PCT No.: PCT/EP2009/008920 temozolomide.” QJNuclMed Mol Imaging. Sep. 2004:48(3):220-8. S371 (c)(1) Marlind, J., et al. "Antibody-mediated delivery of interleukin-2 to the (2), (4) Date. Jun. 14, 2011 Stroma of breast cancer strongly enhances the potency of chemo s 9 therapy” Clin Cancer Res. Oct. 15, 2008;14(20):6515-24. Brack, S.S., et al. “Tumor-targeting properties of novel antibodies (87) PCT Pub. No.: WO2010/078916 specific to the large isoform oftenascin-C.” Clin Cancer Res.
    [Show full text]
  • Ep 2569287 B1
    (19) TZZ _T (11) EP 2 569 287 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 413/04 (2006.01) C07D 239/46 (2006.01) 09.07.2014 Bulletin 2014/28 (86) International application number: (21) Application number: 11731562.2 PCT/US2011/036245 (22) Date of filing: 12.05.2011 (87) International publication number: WO 2011/143425 (17.11.2011 Gazette 2011/46) (54) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERBINDUNGEN ALS HEMMER DER ATR-KINASE COMPOSÉS UTILISABLES EN TANT QU’INHIBITEURS DE LA KINASE ATR (84) Designated Contracting States: • VIRANI, Aniza, Nizarali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abingdon GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oxfordshire OX144RY (GB) PL PT RO RS SE SI SK SM TR • REAPER, Philip, Michael Abingdon (30) Priority: 12.05.2010 US 333869 P Oxfordshire OX144RY (GB) (43) Date of publication of application: (74) Representative: Coles, Andrea Birgit et al 20.03.2013 Bulletin 2013/12 Kilburn & Strode LLP 20 Red Lion Street (73) Proprietor: Vertex Pharmaceuticals Inc. London WC1R 4PJ (GB) Boston, MA 02210 (US) (56) References cited: (72) Inventors: WO-A1-2010/054398 WO-A1-2010/071837 • CHARRIER, Jean-Damien Abingdon • C. A. HALL-JACKSON: "ATR is a caffeine- Oxfordshire OX144RY (GB) sensitive, DNA-activated protein kinase with a • DURRANT, Steven, John substrate specificity distinct from DNA-PK", Abingdon ONCOGENE, vol. 18, 1999, pages 6707-6713, Oxfordshire OX144RY (GB) XP002665425, cited in the application • KNEGTEL, Ronald, Marcellus Alphonsus Abingdon Oxfordshire OX144RY (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • UCSD Moores Cancer Center Neuro-Oncology Program
    UCSD Moores Cancer Center Neuro-Oncology Program Recent Progress in Brain Tumors 6DQWRVK.HVDUL0'3K' 'LUHFWRU1HXUR2QFRORJ\ 3URIHVVRURI1HXURVFLHQFHV 0RRUHV&DQFHU&HQWHU 8QLYHUVLW\RI&DOLIRUQLD6DQ'LHJR “Brain Cancer for Life” Juvenile Pilocytic Astrocytoma Metastatic Brain Cancer Glioblastoma Multiforme Glioblastoma Multiforme Desmoplastic Infantile Ganglioglioma Desmoplastic Variant Astrocytoma Medulloblastoma Atypical Teratoid Rhabdoid Tumor Diffuse Intrinsic Pontine Glioma -Mutational analysis, microarray expression, epigenetic phenomenology -Age-specific biology of brain cancer -Is there an overlap? ? Neuroimmunology ? Stem cell hypothesis Courtesy of Dr. John Crawford Late Effects Long term effect of chemotherapy and radiation on neurocognition Risks of secondary malignancy secondary to chemotherapy and/or radiation Neurovascular long term effects: stroke, moya moya Courtesy of Dr. John Crawford Importance Increase in aging population with increased incidence of cancer Patients with cancer living longer and developing neurologic disorders due to nervous system relapse or toxicity from treatments Overview Introduction Clinical Presentation Primary Brain Tumors Metastatic Brain Tumors Leptomeningeal Metastases Primary CNS Lymphoma Paraneoplastic Syndromes Classification of Brain Tumors Tumors of Neuroepithelial Tissue Glial tumors (astrocytic, oligodendroglial, mixed) Neuronal and mixed neuronal-glial tumors Neuroblastic tumors Pineal parenchymal tumors Embryonal tumors Tumors of Peripheral Nerves Shwannoma Neurofibroma
    [Show full text]
  • 5 Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation
    Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation 67 5 Combinations of Hypoxia-Targeting Compounds and Radiation-Activated Prodrugs with Ionizing Radiation G-One Ahn and J. Martin Brown CONTENTS 5.1 Targeting Tumor Hypoxia 5.1 Targeting Tumor Hypoxia 67 5.2 Oxygen-Level Enhancers 68 5.3 Hypoxia-Selective Radiosensitizers 69 Tumor hypoxia was first postulated from histo- 5.3.1 Nitroimidazoles 69 logical studies of human lung adenocarcinomas by 5.3.2 Mixed-Function Radiosensitizers 69 Thomlinson and Gray (1955). They reasoned that, 5.3.3 DNA-Affinic Radiosensitizers 71 because of unrestrained growth, tumor cells are 5.3.4 Limitations of HSR 71 forced away from blood vessels beyond the effec- 5.4 Hypoxic Cytotoxins 72 5.4.1 Introduction 72 tive diffusion distance of oxygen (O2) in respiring 5.4.2 Combination of Hypoxic Cytotoxins with Ionizing tissues, hence becoming hypoxic and eventually Radiation 72 necrotic (Fig. 5.1a). Given the typical values for 5.4.3 Nitroimidazoles 73 intracapillary O2 tensions and consumption rates, 5.4.4 Other Nitroaromatics 73 they calculated that O diffusion distances would 5.4.4.1 CB 1954 73 2 be approximately 150 Pm and this was consistent 5.4.4.2 SN 23862 and PR-104 74 Thomlinson 5.4.4.3 RSU 1069 and RB 6145 74 with their histological observations ( 5.4.5 Quinones 75 and Gray 1955). This type of hypoxia has come to be 5.4.5.1 Mitomycin C 75 termed “chronic,” or “diffusion-limited,” hypoxia. 5.4.5.2 Porfiromycin 75 Acute hypoxia also develops in tumors through 5.4.5.3 EO9 75 temporal (reversible) cessation or reduction of 5.4.6 Benzotriene di-N-Oxides 76 5.4.7 Tertiary Amine N-Oxides 78 tumor blood flow resulting from highly disorga- 5.4.7.1 Nitracrine N-Oxides 78 nized tumor vasculature (Fig.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]